Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

This study is evaluating a blood test (circulating tumor DNA, or ctDNA) that detects tiny traces of cancer remaining after surgery in a diverse group of patients with early-stage breast cancer, to see how well it predicts cancer recurrence. **You may be eligible if...** - You are 18 or older - You have had surgery for early-stage breast cancer - Tissue from your tumor or lymph nodes is available from the surgery for ctDNA testing - You are willing to comply with study procedures **You may NOT be eligible if...** - You received chemotherapy or hormone therapy before surgery (neoadjuvant therapy) - Imaging has shown evidence of cancer spread (metastatic disease) - You only have very small isolated cancer cells found in lymph nodes (called N1 mic or isolated tumor cells) Talk to your doctor to see if this trial is right for you.